1. Maurer M, Church MK, Gonçalo M, Sussman G, Sánchez-Borges M. Management and treatment of chronic urticaria (CU). J Eur Acad Dermatol Venereol. 2015 Jun;29 Suppl 3:16-32.

2. Giménez-Arnau AM, Toubi E, Marsland AM, Maurer M. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2016;30 Suppl 5:25-32.

3. Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T, Wei JF, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a metaanalysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742‑50.

4. Ensina LF, Valle SO, Juliani AP, Galeane M, Vieira dos Santos R, Arruda LK, et al. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian real-life experience. Int Arch Allergy Immunol. 2016;169(2):121-4.

5. Maurer M, Sofen H, Ortiz B, Kianifard F, Gabriel S, Bernstein JA. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol. 2016 Dec 2. doi: 10.1111/jdv.14075.

6. Zazzali JL, Kaplan A, Maurer M, Raimundo K, Trzaskoma B, Solari PG, et al. Angioedema in the omalizumab chronic idiopathic/ spontaneous urticaria pivotal studies. Ann Allergy Asthma Immunol. 2016;117(4):370-7.

7. Staubach P, Metz M, Chapman-Rothe N, Sieder C, Bräutigam M, Canvin J, et al. Effect of omalizumab on angioedema in H1-antihistamineresistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy. 2016;71(8):1135-44.

8. Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135(2):337‑42.

9. Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in Chronic Spontaneous Urticaria. Allergy. 2016 Nov 15. doi: 10.1111/all.13083.

10. Fine LM, Bernstein JA. Guideline of Chronic Urticaria Beyond. Allergy Asthma Immunol Res. 2016;8(5):396-403.

11. Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma B, Raimundo K, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137(2):474-81.

12. Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol. 2012;129:1307-13.

13. Dionigi PC, Menezes MC, Forte WC. A prospective ten-year follow-up of patients with chronic urticaria. Allergol Immunopathol (Madr). 2016;44(4):286-91.

14. Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2016 Oct 21. pii: S0091-6749(16)31212-X. doi: 10.1016/j.jaci.2016.08.050.

15. Calamita Z1, Pelá Calamita AB. Chronic spontaneous urticaria: epidemiological characteristics focusing on the histocompatibility profile and presence of antibodies. Inflamm Allergy Drug Targets. 2013;12(1):8-11.

16. Sanjuan MA, Sagar D, Kolbeck R. Role of IgE in autoimmunity. J Allergy Clin Immunol. 2016 Jun;137(6):1651-61.

17. Grattan CE, Wallington TB, Warin RP, Kennedy CT, Bradfield JW. A serological mediator in chronic idiopathic urticaria – a clinical, immunological and histological evaluation. Br J Dermatol. 1986;114:583-90.

18. Ferriani MP, Silva MF, Pereira RM, Terreri MT, Saad Magalhães C, Bonfá E et al. Chronic Spontaneous Urticaria: a survey of 852 cases of childhood-onset Systemic Lupus Erythematosus. Int Arch Allergy Immunol. 2015;167(3):186-92.

19. Lawrence MG, Woodfolk JA, Schuyler AJ, Stillman LC, Chapman MD, Platts-Mills TA. Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease. J Allergy Clin Immunol. 2016 Jul 14. pii: S0091-6749(16)30600-5. doi: 10.1016/j. jaci.2016.04.056.

20. Asero R, Tedeschi A, Marzano AV, Cugno M. Chronic spontaneous urticaria: immune system, blood coagulation, and more. Expert Rev Clin Immunol. 2016;12(3):229-31.

21. Criado PR, Criado RFJ, Maruta CW, Reis VMS. Chronic urticaria in adults: state-of-the-art in the new millennium. An Bras Dermatol. 2015;90(1):74-89.

22. Cugno M, Tedeschi A, Borghi A, Bucciarelli P, Asero R, Venegoni L, et al. Activation of blood coagulation in two prototypic autoimmune skin diseases: a possible link with thrombotic risk. PLoS One. 2015;10(6):e0129456. doi: 10.1371/journal.pone.0129456.

23. Yalcin AD, Celik B, Gumuslu S. D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment. Expert Opin Biol Ther. 2014;14(3):283-6.

24. Criado PC, Maruta CW, Antinori LCL, Reis VMS. Evaluation of D-dimer serum levels among patients with chronic urticaria, psoriasis and urticarial vasculitis. An Bras Dermatol. 2013;88(3):355-60.

25. Eggel A, Baravalle G, Hobi G, Kim B, Buschor P, Forrer P, et al. Accelerated dissociation of IgE-FcRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol 2014;133(6):1709-19.

26. Serrano-Candelas E, Martinez-Aranguren R, Valero A, Bartra J, Gastaminza G, Goikoetxea MJ, et al. Comparable actions of omalizumab on mast cells and basophils. Clin Exp Allergy. 2016 Jan;46(1):92-102.

27. Gericke J, Metz M, Ohanyan T, Weller K, Altrichter S, Skov PS, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2016 Nov 9. pii: S0091-6749(16)31282-9. doi: 10.1016/j. jaci.2016.07.047.

28. Weller K, Siebenhaar F, Hawro T, Altrichter S, Schoepke N, Maurer M. Clinical measures of Chronic Urticaria. Immunol Allergy Clin North Am. 2017 Feb;37(1):35-49. doi: 10.1016/j.iac.2016.08.005.

29. Valle SO, Motta AA, Amaral CS, Ensina LF, Mallozi MC, Spengler MG, et al. O que há de novo na urticária crônica espontânea? Braz J Allergy Immunol. 2016;4(1):9-25.

30. Mathias SD, Crosby RD, Zazzali JL, Maurer M, Saini SS. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012;108(1):20-4.

31. Mathias SD, Crosby RD, Rosén KE, Zazzali JL. The minimal important difference for measures of urticaria disease activity: Updated findings. Allergy Asthma Proc. 2015;36(5):394-8.

32. Rabelo-Filardi R, Daltro-Oliveira R, Campos RA. Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review. Int Arch Allergy Immunol. 2013;161(3):197‑204.

33. Kolkhir P, Andre F, Church MK, Maurer M, Metz M. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy. 2016 Dec 7. doi: 10.1111/cea.12870.

34. Altrichter S, Hawro T, Hänel K, Czaja K, Lüscher B, Maurer M, et al. Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels. J Eur Acad Dermatol Venereol. 2016;30(3):454-5.

35 Bulkhi A, Cooke AJ, Casale TB. Biologics in Chronic Urticaria. Immunol Allergy Clin North Am. 2017;37(1):95-112. doi: 10.1016/j. iac.2016.08.004.